Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Shares Issued (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Shares Issued for 14 consecutive years, with $870000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued fell 66.95% to $870000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 54.08% decrease, with the full-year FY2024 number at $2.9 million, up 405.84% from a year prior.
  • Shares Issued was $870000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from $614000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $2.6 million in Q3 2024 to a low of -$2.0 million in Q4 2021.
  • A 4-year average of $646000.0 and a median of $614000.0 in 2025 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 362073.04% in 2021; the steepest drop was 39980.0% in 2021.
  • NovaBay Pharmaceuticals' Shares Issued stood at -$2.0 million in 2021, then surged by 120.06% to $400000.0 in 2023, then soared by 558.0% to $2.6 million in 2024, then plummeted by 66.95% to $870000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Shares Issued are $870000.0 (Q3 2025), $614000.0 (Q1 2025), and $2.6 million (Q3 2024).